Biomarker Tests for Molecularly Targeted Therapies--The Key to Unlocking Precision Medicine

Gary H Lyman1, Harold L Moses1

  • 1From the Fred Hutchinson Cancer Research Center and the University of Washington - both in Seattle (G.H.L.); the Committee on Policy Issues in the Clinical Development and Use of Biomarkers for Molecularly Targeted Therapies, National Academies of Sciences, Engineering, and Medicine, Washington, DC (G.H.L., H.L.M.); and Vanderbilt University, Nashville (H.L.M.).

Abstract

No abstract available in PubMed .